Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial".
Saved in:
| Title: | Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial". |
|---|---|
| Authors: | Nishida N; Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan. |
| Source: | Clinical and molecular hepatology [Clin Mol Hepatol] 2025 Jan; Vol. 31 (1), pp. 311-315. Date of Electronic Publication: 2024 Sep 03. |
| Publication Type: | Editorial |
| Journal Info: | Publisher: Korean Association for the Study of the Liver Country of Publication: Korea (South) NLM ID: 101586730 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2287-285X (Electronic) Linking ISSN: 22872728 NLM ISO Abbreviation: Clin Mol Hepatol Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 39228069 AccessLevel: 2 PubType: Editorial & Opinion PubTypeId: editorialOpinion PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial". – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Nishida+N%22">Nishida N</searchLink>; Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101586730%22">Clinical and molecular hepatology</searchLink> [Clin Mol Hepatol] 2025 Jan; Vol. 31 (1), pp. 311-315. <i>Date of Electronic Publication: </i>2024 Sep 03. – Name: TypePub Label: Publication Type Group: TypPub Data: Editorial – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Korean+Association+for+the+Study+of+the+Liver%22">Korean Association for the Study of the Liver </searchLink><i>Country of Publication: </i>Korea (South) <i>NLM ID: </i>101586730 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2287-285X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2222872728%22">22872728 </searchLink><i>NLM ISO Abbreviation: </i>Clin Mol Hepatol <i>Subsets: </i>MEDLINE; In Process |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39228069 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.3350/cmh.2024.0739 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 311 Titles: – TitleFull: Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial". Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Nishida N IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 01 Text: 2025 Jan Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 2287-285X Numbering: – Type: volume Value: 31 – Type: issue Value: 1 Titles: – TitleFull: Clinical and molecular hepatology Type: main |
| ResultId | 1 |
